Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1D1 | P20393 | 1/20 | 0.47 |
| ▸ | MMP1 | P03956 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | MMP8 | P22894 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3153356 | 0.89 | NR1D1 (0.49) | NR1D1MMP1MMP2MMP9MMP8 | |
| SCHEMBL6243655 | 0.82 | HDAC3 (0.37) | — | |
| SCHEMBL25934543 | 0.82 | L3MBTL1 (0.49) | — | |
| SCHEMBL4445852 | 0.81 | NR1D1 (0.44) | NR1D1 | |
| SCHEMBL4445860 | 0.81 | NR1D1 (0.44) | NR1D1 | |
| SCHEMBL16682350 | 0.80 | NR1D1 (0.53) | NR1D1MMP1MMP2MMP9MMP8 | |
| SCHEMBL1799639 | 0.80 | NR1D1 (0.50) | NR1D1MMP1MMP2MMP9MMP8 | |
| SCHEMBL3156438 | 0.79 | NR1D1 (0.52) | NR1D1MMP1MMP2MMP9MMP8 | |
| SCHEMBL3161371 | 0.78 | NR1D1 (0.48) | NR1D1MMP1MMP2MMP9MMP8 | |
| SCHEMBL16682346 | 0.77 | NR1D1 (0.53) | NR1D1MMP1MMP2MMP9MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050043381-A1 | Aminopyrazole compounds | AGOURON PHARMACEUTICALS, INC. | 2005-02-24 | — | — | US | disclosed |
| WO-2005009435-A1 | AMINOPYRAZOLE COMPOUNDS AND USE AS CHK1 INHIBITORS | PFIZER INC. (US) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043381-A1 | Aminopyrazole compounds | CDK1, CDK3, BUB1B | NR1D1 1011/4885MMP1 4451/4885MMP2 4715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.